Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial - Wikidata - awgldk - TriplyDB

Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

http://www.wikidata.org/entity/Q33751427

about

Intensive versus conventional glycaemic control for treating diabetic foot ulcers Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survival Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes Cardiac autonomic testing and diagnosing heart disease. "A clinical perspective"Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement Glycemic control and cardiovascular disease: what's a doctor to do?Pathways in the diagnosis and management of diabetic polyneuropathy Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015.Treating Diabetic Neuropathy: Present Strategies and Emerging Solutions.Measuring quality of life of old type 2 diabetic patients in primary care in Portugal: a cross-sectional study Long-term effects of intensive glucose lowering on cardiovascular outcomes.The ECG vertigo in diabetes and cardiac autonomic neuropathy.Cardiovascular disease in diabetes: where does glucose fit in?Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial Medication use in older U.S. adults with diabetes mellitus and the potential ramifications of raising the glycemic target Glycemia and cardiovascular risk: challenging evidence based medicine.Differences between Western and Asian type 2 diabetes patients in the incidence of vascular complications and mortality: A systematic review of randomized controlled trials on lowering blood glucose.Treatment with α-Lipoic Acid over 16 Weeks in Type 2 Diabetic Patients with Symptomatic Polyneuropathy Who Responded to Initial 4-Week High-Dose Loading.Determinants of mortality in patients with type 2 diabetes: a review.Cardiovascular risk reduction following diagnosis of diabetes by screening: 1-year results from the ADDITION-Cambridge trial cohort.The conductor of the autonomic orchestra.Spatial analysis improves the detection of early corneal nerve fiber loss in patients with recently diagnosed type 2 diabetes Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease.Is hyperglycemia a cardiovascular risk factor?Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials.Glucose control and diabetic neuropathy: lessons from recent large clinical trials.Insulin therapy in people with type 2 diabetes: opportunities and challenges?Strength training as a countermeasure to aging muscle and chronic disease.Control of postprandial glucose levels with insulin in type 2 diabetes.Differential effects of adrenergic antagonists (Carvedilol vs Metoprolol) on parasympathetic and sympathetic activity: a comparison of clinical results Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study.

P2860

Q24186487-8B47EB3C-B046-47C4-8090-B3B869F45B44 Q24186667-9FA37A6E-645A-4464-B598-59EB2E5DE369 Q24202505-FA929EC8-4CBE-493E-B3DF-83BE2D85C77B Q24236456-FAF4F620-084A-4AED-9450-6DBE36353167 Q26827620-56FFBBA8-F070-415B-B1BE-AB9C204472E9 Q26866924-181415D7-FE51-4788-9FB6-B9F52FDCB103 Q26998895-F4793A8A-E3A4-4226-B276-AD3395B63DB7 Q27003819-4C0036C0-3502-42B6-8D6C-84B74CA278B8 Q27024469-FEEEB781-6369-449D-A7A9-98C85B92A9FB Q28082465-BE8DC0D9-B19F-488E-A2B7-60658E1278CB Q30276113-8154930D-0DA9-4A3C-BBBF-771E44DE351A Q33583001-B6250B61-9A3A-44F2-9DE1-7455EB4039AF Q33583006-EC47A5B4-BA51-4949-8E64-DBF88EDB83D8 Q33796751-29E00249-842A-4F8C-B2CB-1E1397E8F43D Q33851861-A0366E5D-A5FD-4C6C-A9B1-772006AE7A12 Q35071142-19959D18-5DC2-440B-A2DE-CE3FE540C453 Q35137148-738CB3A4-973F-478A-8630-2CE9E91CFF06 Q35234653-96679E15-E778-4E23-A923-664D2A579B05 Q35630701-62DC6FC6-45AD-4B67-875F-E3321218343E Q35632627-A381DAF2-BDC7-470D-9ECD-10BBD4BD6772 Q35835351-F1AF23F3-50C4-4494-B406-35C879A51DF0 Q35867921-8BE19A4B-162C-4A80-A5B0-6295EAAA0231 Q35964005-FB2E1470-A5A4-4576-9B16-E33C24C9AC15 Q35986709-75002040-BD33-4EA1-9C76-3C4BEC808EE4 Q35990657-CB2AC163-91B4-442F-AA50-DD844183F103 Q36050086-421AF99F-3360-4DEC-A04E-272063FAF2E2 Q36309112-096B0AF8-D4EF-4E94-8D3D-2A00AFC6BEC2 Q36634416-D8850C9F-71E8-41A2-A12B-9DC57789EA81 Q36783705-EC83087C-2559-4AD0-A86E-E93AC36A32C5 Q36820609-542CB35F-27B2-44C2-8ED7-9C69356BCFFF Q37011769-803E9302-E1E4-472B-8881-1668A8BAF846 Q37023878-D29383B1-7AFC-458C-9592-5BB5DFEFA114 Q37375113-33386199-0A8B-414C-AD90-91D62BCF8908 Q37461707-5F27C51A-439E-4165-B213-DBEE59F8F75C Q37855784-28F97450-91BB-4B78-8E52-8A3183D5E884 Q37890790-72E78825-46C9-4AAD-9346-6BD7333817C1 Q38725614-CD9E3C08-0CD9-4EA4-B787-F5CF4E82BE80 Q38798588-695F6D56-FD32-4F82-8E49-8E8696114E85 Q38967759-9980ABA3-3C7C-4FA0-A42C-DE2461E2C7BA Q41054147-41F9B1CF-19FA-4131-93EA-CF38C371E905

P2860

Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

http://www.wikidata.org/entity/Q33751427

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Effect of intensive compared w ...... isk in Diabetes (ACCORD) trial

@ast

Effect of intensive compared w ...... isk in Diabetes (ACCORD) trial

@en

type

label

Effect of intensive compared w ...... isk in Diabetes (ACCORD) trial

@ast

Effect of intensive compared w ...... isk in Diabetes (ACCORD) trial

@en

prefLabel

Effect of intensive compared w ...... isk in Diabetes (ACCORD) trial

@ast

Effect of intensive compared w ...... isk in Diabetes (ACCORD) trial

@en

P1433

Q33751427-5CD297AB-A1D7-48E5-9BDF-1F7854C574CE

P1476

Q33751427-40CC82F5-353E-4521-B824-E38ABD39EEFE

P2093

Q33751427-05C27571-A8ED-4661-9EDC-13D52D5CA62A

Q33751427-137A4543-608D-4233-8752-B2D037264F67

Q33751427-4E650BDA-6A2E-4C7A-8E55-42A8D6A4C398

Q33751427-71945ECB-71E5-4EAD-B6A0-88CCC529CFDB

Q33751427-8CD34C4A-4914-4583-9393-8E917E17CF36

Q33751427-A728A790-5F41-4C75-9E68-69917CF31503

Q33751427-B97D766C-D522-4C0C-97E7-E09A5D381015

Q33751427-D310B343-BAFF-4F68-8B04-296629BB9605

Q33751427-E09F1FF7-43C7-4B35-91F1-F7696A398527

Q33751427-E591A199-4336-4F7E-BF04-E3AE2FDD53E5

P2860

Q33751427-126F87F2-A23D-48D2-923E-9BEAE7B1E61D

Q33751427-128EEDB1-43B1-4899-A978-AC74255DE434

Q33751427-233C2446-054C-4FE2-935C-956FC159E0F5

Q33751427-25394454-C6CA-49A2-87F5-44FCAA94F6ED

Q33751427-2CECE909-3D01-4A47-BA6D-86A1D2D0CE5E

Q33751427-3D80D248-0336-4079-A1E7-4E4F118E7E1F

Q33751427-4A4B289F-6B79-4F50-99FE-2BB82EEF1F82

Q33751427-53738EB6-23BB-4C99-9A81-C56579BD47EB

Q33751427-6DAC8D08-5C93-41B3-8FA5-158329B866B7

Q33751427-6FC70B1A-1343-499A-BC8D-39F6AA338D79

P304

Q33751427-04D8D364-73AE-4F7D-808F-D8F4BC3EAAE4

P31

Q33751427-FAEBB3EF-CA0E-4D0A-90BD-A440747912F1

P356

Q33751427-CB77DA82-3344-493A-8101-7EE791FCFDFA

P407

Q33751427-31797A49-A6CF-4489-98D1-A22FBBA5BE7E

P433

Q33751427-6E648F06-D272-49AB-9600-B58F86D7866C

P478

Q33751427-EBA88A0B-AFB0-4B78-ACA8-AD14745702CD

P50

Q33751427-B59232DC-F1DB-45B0-9916-639B33A27736

P577

Q33751427-9DE1F4DE-3E41-4C55-8E1B-C307DD5EEFBF

P5875

Q33751427-B52CFC1C-464B-45DC-A604-24353EF59DFF

P698

Q33751427-6660F3D6-ABB1-4C6A-9A89-ACFA58C234E8

P921

Q33751427-F99778CA-8C18-4FAA-A05B-815DA7A3BC8E

P932

Q33751427-F5507666-66D0-404D-A2CC-E6A5B299AF6D

P356

P1433

P1476

Effect of intensive compared w ...... isk in Diabetes (ACCORD) trial

@en

P2093

Alan Failor

http://www.w3.org/2001/XMLSchema#string

Bruce Hamilton

http://www.w3.org/2001/XMLSchema#string

David M Kendall

http://www.w3.org/2001/XMLSchema#string

Denise E Bonds

http://www.w3.org/2001/XMLSchema#string

Denise G Simons-Morton

http://www.w3.org/2001/XMLSchema#string

Faramarz Ismail-Beigi

http://www.w3.org/2001/XMLSchema#string

Jorge Calles-Escandón

http://www.w3.org/2001/XMLSchema#string

Laura C Lovato

http://www.w3.org/2001/XMLSchema#string

Mary Ann Banerji

http://www.w3.org/2001/XMLSchema#string

Robert M Cohen

http://www.w3.org/2001/XMLSchema#string

P2860

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

Associations of mortality and diabetes complications in patients with type 1 and type 2 diabetes: early treatment diabetic retinopathy study report no. 27

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Glucose control and vascular complications in veterans with type 2 diabetes

Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

Glycemic control in type 2 diabetes: time for an evidence-based about-face?

Standards of medical care in diabetes--2009.

P304

721-727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-1471

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Rodica Pop-Busui

P577

2010-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41148546

http://www.w3.org/2001/XMLSchema#string

P698

20103550

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

2845012

http://www.w3.org/2001/XMLSchema#string